Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia

This meta-analysis assesses the psychopathological outcomes in healthy volunteers and patients with schizophrenia treated with ketamine and the experimental factors associated with these findings.

[1]  O. Howes,et al.  The Efficacy and Heterogeneity of Antipsychotic Response in Schizophrenia: A Meta-analysis , 2019, Molecular Psychiatry.

[2]  C. Morgan,et al.  Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function , 2018, Translational Psychiatry.

[3]  G. McCarthy,et al.  Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects , 2018, Biological Psychiatry.

[4]  W. Singer,et al.  Acute ketamine dysregulates task-related gamma-band oscillations in thalamo-cortical circuits in schizophrenia , 2018, Brain : a journal of neurology.

[5]  Lynnette A. Averill,et al.  The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects , 2018, Neuropsychopharmacology.

[6]  Nancy C. Andreasen,et al.  Scale for the Assessment of Positive Symptoms , 2018 .

[7]  R. Shelton,et al.  Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial , 2017, JAMA psychiatry.

[8]  W. Drevets,et al.  Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study , 2016, Psychopharmacology.

[9]  O. Howes,et al.  Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia: A Meta-analysis , 2017, JAMA psychiatry.

[10]  J. Verster,et al.  The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study , 2017, Psychopharmacology.

[11]  J. Gallinat,et al.  Glutamatergic deficit and schizophrenia-like negative symptoms: new evidence from ketamine-induced mismatch negativity alterations in healthy male humans , 2017, Journal of psychiatry & neuroscience : JPN.

[12]  Naomi S. Kort,et al.  Role of N-Methyl-D-Aspartate Receptors in Action-Based Predictive Coding Deficits in Schizophrenia , 2017, Biological Psychiatry.

[13]  Mark S. Bolding,et al.  Ketamine Modulates Hippocampal Neurochemistry and Functional Connectivity – A Combined Magnetic Resonance Spectroscopy and Resting State fMRI Study in Healthy Volunteers , 2016, Molecular Psychiatry.

[14]  Mike W-L Cheung,et al.  Random‐effects models for meta‐analytic structural equation modeling: review, issues, and illustrations , 2016, Research synthesis methods.

[15]  E. Finn,et al.  Ketamine-Induced Hallucinations , 2015, Psychopathology.

[16]  Christian Windischberger,et al.  Ketamine-Induced Modulation of the Thalamo-Cortical Network in Healthy Volunteers As a Model for Schizophrenia , 2015, The international journal of neuropsychopharmacology.

[17]  Alan A. Wilson,et al.  Reduced Insulin Sensitivity Is Related to Less Endogenous Dopamine at D2/3 Receptors in the Ventral Striatum of Healthy Nonobese Humans , 2015, The international journal of neuropsychopharmacology.

[18]  A. Dahan,et al.  Optimizing the glutamatergic challenge model for psychosis, using S(+)-ketamine to induce psychomimetic symptoms in healthy volunteers , 2015, Journal of psychopharmacology.

[19]  N. Andreasen.  Scale for the Assessment of Negative Symptoms , 2014 .

[20]  M. Leboyer,et al.  Ketamine administration in depressive disorders: a systematic review and meta-analysis , 2014, Psychopharmacology.

[21]  R. Lam,et al.  A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes , 2014, Psychological Medicine.

[22]  J. Ford,et al.  Effects of Nicotine on the Neurophysiological and Behavioral Effects of Ketamine in Humans , 2013, Front. Psychiatry.

[23]  Dimitris Mavridis,et al.  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis , 2013, The Lancet.

[24]  P. Cumming,et al.  Vulnerability to psychotogenic effects of ketamine is associated with elevated D2/3-receptor availability. , 2013, The international journal of neuropsychopharmacology.

[25]  G. McCarthy,et al.  Relationship of Resting Brain Hyperconnectivity and Schizophrenia-like Symptoms Produced by the NMDA receptor Antagonist Ketamine in Humans , 2012, Molecular Psychiatry.

[26]  D. D’Souza,et al.  Nicotine Fails to Attenuate Ketamine-Induced Cognitive Deficits and Negative and Positive Symptoms in Humans: Implications for Schizophrenia , 2012, Biological Psychiatry.

[27]  Richard D Riley,et al.  A multivariate meta‐analysis approach for reducing the impact of outcome reporting bias in systematic reviews , 2012, Statistics in medicine.

[28]  Daniel J Fridberg,et al.  Dose-Related Modulation of Event-Related Potentials to Novel and Target Stimuli by Intravenous Δ9-THC in Humans , 2012, Neuropsychopharmacology.

[29]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[30]  Tracy Warbrick,et al.  Ketamine effects on brain function — Simultaneous fMRI/EEG during a visual oddball task , 2011, NeuroImage.

[31]  Jack Bowden,et al.  Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics , 2011, BMC medical research methodology.

[32]  Tilo Kircher,et al.  Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency , 2011, NeuroImage.

[33]  Danielle C. Turner,et al.  Exploring the Impact of Ketamine on the Experience of Illusory Body Ownership , 2011, Biological Psychiatry.

[34]  M. Allin,et al.  Ketamine-induced disruption of verbal self-monitoring linked to superior temporal activation. , 2010, Pharmacopsychiatry.

[35]  G. Antes,et al.  CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials , 2011 .

[36]  Wolfgang Viechtbauer,et al.  Conducting Meta-Analyses in R with the metafor Package , 2010 .

[37]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[38]  D. Moher,et al.  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, BMC medicine.

[39]  J. Krystal,et al.  Ethanol-like effects of thiopental and ketamine in healthy humans , 2010, Journal of psychopharmacology.

[40]  H. Holcomb,et al.  The interactive effects of ketamine and nicotine on human cerebral blood flow , 2010, Psychopharmacology.

[41]  F. Španiel,et al.  Subanesthetic dose of ketamine decreases prefrontal theta cordance in healthy volunteers: implications for antidepressant effect , 2009, Psychological Medicine.

[42]  Erin R. Reichenberger,et al.  Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: A double-blind placebo controlled study , 2009, PAIN®.

[43]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].

[44]  L. Soufflet,et al.  Ketamine effects on CNS responses assessed with MEG/EEG in a passive auditory sensory-gating paradigm: an attempt for modelling some symptoms of psychosis in man , 2007, Journal of psychopharmacology.

[45]  J. Cramer,et al.  Psychiatric safety of ketamine in psychopharmacology research , 2007, Psychopharmacology.

[46]  J. Krystal,et al.  Greater vulnerability to the amnestic effects of ketamine in males , 2006, Psychopharmacology.

[47]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[48]  A. Belger,et al.  Potentiation of Low Dose Ketamine Effects by Naltrexone: Potential Implications for the Pharmacotherapy of Alcoholism , 2006, Neuropsychopharmacology.

[49]  H. Holcomb,et al.  Effects of Noncompetitive NMDA Receptor Blockade on Anterior Cingulate Cerebral Blood Flow in Volunteers with Schizophrenia , 2005, Neuropsychopharmacology.

[50]  Stefan Leucht,et al.  What does the PANSS mean? , 2005, Schizophrenia Research.

[51]  A. Lahti,et al.  The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers , 2005, Psychopharmacology.

[52]  A. Belger,et al.  Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. , 2005, Archives of general psychiatry.

[53]  R. Astur,et al.  Selective Cognitive Impairments Associated with NMDA Receptor Blockade in Humans , 2005, Neuropsychopharmacology.

[54]  A. Belger,et al.  Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine , 2005, Psychopharmacology.

[55]  J. Krystal,et al.  Altered NMDA Glutamate Receptor Antagonist Response in Recovering Ethanol-Dependent Patients , 2003, Neuropsychopharmacology.

[56]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[57]  Steve Williams,et al.  Ketamine and fMRI BOLD signal: Distinguishing between effects mediated by change in blood flow versus change in cognitive state , 2003, Human brain mapping.

[58]  H. Emrich,et al.  Effects of different subanaesthetic doses of (S)-ketamine on psychopathology and binocular depth inversion in man , 2003, Journal of psychopharmacology.

[59]  Thierry Hasbroucq,et al.  Effects of Subanesthetic Doses of Ketamine on Sensorimotor Information Processing in Healthy Subjects , 2002, Clinical neuropharmacology.

[60]  Franz X Vollenweider,et al.  A systems model of altered consciousness: integrating natural and drug-induced psychoses , 2001, Brain Research Bulletin.

[61]  H. Holcomb,et al.  Probing the human hippocampus using rCBF: Contrasts in schizophrenia , 2001, Hippocampus.

[62]  C. Tamminga,et al.  Effects of Ketamine in Normal and Schizophrenic Volunteers , 2001, Neuropsychopharmacology.

[63]  Erica Duncan,et al.  Clinical and Sensorimotor Gating Effects of Ketamine in Normals , 2001, Neuropsychopharmacology.

[64]  C. Tamminga,et al.  Long-term outcome of patients who receive ketamine during research , 2001, Biological Psychiatry.

[65]  J. Olney,et al.  A comparative evaluation of the neurotoxic properties of ketamine and nitrous oxide , 2001, Brain Research.

[66]  D. Javitt,et al.  Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. , 2000, Archives of general psychiatry.

[67]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[68]  J. Krystal,et al.  Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. , 2000, Archives of general psychiatry.

[69]  D. Cyril D’Souza,et al.  Interactive effects of subanesthetic ketamine and haloperidol in healthy humans , 1999, Psychopharmacology.

[70]  Tamara Hershey,et al.  Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis , 1999, Neuropsychopharmacology.

[71]  A. Malhotra,et al.  The Apolipoprotein E ε4 Allele Is Associated with Blunting of Ketamine-Induced Psychosis in Schizophrenia: A Preliminary Report , 1998, Neuropsychopharmacology.

[72]  R. Kahn,et al.  The effects of low dose ketamine on sensory gating, neuroendocrine secretion and behavior in healthy human subjects , 1998, Psychopharmacology.

[73]  J P Vandenbroucke,et al.  Bias in meta-analysis detected by a simple, graphical test , 1998 .

[74]  D. Cyril D’Souza,et al.  Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans , 1998, Psychopharmacology.

[75]  A. Malhotra,et al.  Clozapine Blunts N-Methyl-d-Aspartate Antagonist-Induced Psychosis: A Study with Ketamine , 1997, Biological Psychiatry.

[76]  Anil K Malhotra,et al.  Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics , 1997, Neuropsychopharmacology.

[77]  A. Malhotra,et al.  Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. , 1997, The American journal of psychiatry.

[78]  C. Tamminga,et al.  Absence of ketamine effects on memory and other cognitive functions in schizophrenia patients. , 1996, Journal of psychiatric research.

[79]  J. Olney,et al.  Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: Potential relevance to schizophrenia? , 1995, Biological Psychiatry.

[80]  R. Neufeld,et al.  Variability in BPRS definitions of positive and negative symptoms , 1995, Schizophrenia Research.

[81]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[82]  D R Medoff,et al.  Ketamine activates psychosis and alters limbic blood flow in schizophrenia , 1995, Neuroreport.

[83]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[84]  W. D. Winters,et al.  Seasonal and sex influences on ketamine-induced analgesia and catalepsy in the rat; a possible role for melatonin , 1986, Neuropharmacology.